Back to Market返回行情

IVF INVO Fertility, Inc.

USHealthcare
$1.13-2.59%ClosedMarket Cap: $1.6M

As of 2026-07-10 16:00

Why IVF matters now

INVO Fertility, Inc. (IVF) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.13 with -2.59% on the session and $1.6M in market capitalization; recent performance reads 1-month +4.90% and YTD -60.11%.

The latest financial table shown here is Q4 2025, with revenue of $1.6M, net income of $475.5K, and EPS of $2.96. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -338.0%.

The latest indexable market news headline is "Why INVO Fertility Stock Is Surging Friday Afternoon" from Benzinga.

Additional event context on this page matters because analyst consensus is Buy with a median target of $20.00; recent insider activity includes Krigsvold Terah Renee filing . These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

0.10

P/S

0.31

EV/EBITDA

-1.35

DCF Value

$-309.22

FCF Yield

-338.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

29.1%

Operating Margin

-103.8%

Net Margin

-340.9%

ROE

-490.0%

ROA

-115.3%

ROIC

-62.0%

Financials

PeriodRevenueNet IncomeEPS
Q4 2025$1.6M$475.5K$2.96
FY 2025$6.8M$-23.3M$-66.11
Q3 2025$1.8M$-2.6M$-1.87
Q2 2025$1.9M$-3.8M$-22.88

Analyst Ratings

Consensus

Buy

Target (Consensus)

$20.00

Target (Median)

$20.00

Target Range

$20.00 - $20.00

Strong Buy: 1Buy: 0Hold: 0Sell: 0Strong Sell: 0

Trading Activity

Insider Trades

Krigsvold Terah Reneeofficer: Chief Financial Officer
Sell2026-01-13
Krigsvold Terah Reneeofficer: Chief Financial Officer
Sell2026-01-13
Krigsvold Terah Reneeofficer: Chief Financial Officer
Sell2026-01-13
Krigsvold Terah Reneeofficer: Chief Financial Officer
Sell2026-01-13
Krigsvold Terah Reneeofficer: Chief Financial Officer
Sell2026-01-13

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

2.33

INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders. The firm was established on January 5, 2007, and its operations are based in Sarasota, Florida.